About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Managed Access Programs for AIN457, Secukinumab | Clinical Trials | Clareo Health

Back to clinical trial search

AVAILABLENCT05583604

Managed Access Programs for AIN457, Secukinumab

The purpose of this registration is to list Managed Access Programs (MAPs) related to AIN457, secukinumab

Lead sponsor: Novartis Pharmaceuticals•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

MAP requests are initiated by a licensed physician.https:// www.novart is.com/healthcare-professionals/managed-access-programs

CONTACT

1-888-669-6682 [email protected]

Novartis Pharmaceuticals

CONTACT

Sponsors

Lead Sponsor

Novartis Pharmaceuticals

CAIN457M2002M - Available - Managed Access Program (MAP) Cohort Treatment Plan CAIN457M2002M to provide access to Secukinumab for adult and adolescent patients with Hidradenitis Suppurativa (HS)

Age

12 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•An independent request should be received from a licensed physician (in some instances from Health Authorities, Institutions or Governments).
•The patient has a serious or life-threatening disease or condition and no comparable or satisfactory alternative therapy is available for diagnosis, monitoring or treatment; patient is not medically eligible for available treatment alternatives or has exhausted all available treatment options.

Exclusion Criteria

•There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.
•The patient must meet any other medical criteria established by the medical experts responsible for the product or by the Health Authority in a country (as applicable).
•Provision of the product will not interfere with the initiation, conduct or completion of a Novartis clinical trial or overall development program.

Related studies

RECRUITINGPhase 2

The Safety and Efficacy of Roflumilast Foam in HS

NCT07263230 · Hidradenitis Suppurativa (HS)

RECRUITINGPhase 2

A Study With CIT-013 in HS Patients

NCT06993233 · Hidradenitis Suppurativa (HS)

Pelashield™ PainGuard™ vs Restrata® in HS Surgery

NCT07316192 · Hidradenitis Suppurativa (HS)

RECRUITINGPhase 1

1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)

NCT07155239 · Hidradenitis Suppurativa (HS)

SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

NCT07021495 · Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 18, 2025Terms

Trial snapshot

StatusAVAILABLE

Phase—

Enrollment—

Start date—

Last updatedDec 18, 2025

Condition

Hidradenitis Suppurativa (HS)

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 18, 2025Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions